Feb 10, 2021
BiondVax Announces Exercise in Full of Underwriter's Over-Allotment Option in Follow-on Offering
Feb 02, 2021
BiondVax Announces Closing of $12.1 Million Follow-on Underwritten Offering
Jan 29, 2021
BiondVax Announces Pricing of $12.1 Million Follow-on Underwritten Offering of American Depositary Shares
Jan 28, 2021
BiondVax Announces Third Quarter 2020 Financial Results & Business Update
Jan 21, 2021
BiondVax Announces Appointment of Amir Reichman as New CEO
Oct 23, 2020
BiondVax Announces Topline Results from Phase 3 Clinical Trial of the M-001 Universal Influenza Vaccine Candidate
Oct 02, 2020
BiondVax Announces At-The-Market (ATM) Equity Offering Program
Aug 20, 2020
BiondVax Announces Second Quarter 2020 Financial Results
Aug 13, 2020
BiondVax Announces Notice of Annual General Meeting of Shareholders and Provides a Clinical Trial Update
Jul 01, 2020
Last of 12,400 Participants Completes Final Visit in BiondVax's M-001 Universal Flu Vaccine Pivotal Phase 3 Clinical Trial
Jun 30, 2020
BiondVax Announces First Quarter 2020 Financial Results
Jun 12, 2020
BiondVax Announces Fourth Quarter and Full Year 2019 Financial Results and Provides Business Update
Jun 10, 2020
NIH Report on Phase 2 Clinical Trial of BiondVax's M-001 Universal Influenza Vaccine Candidate Concludes Both Primary Endpoints Achieved
May 20, 2020
BiondVax Announces Receipt of $4.2 Million Through Exercise of Warrants
May 04, 2020
BiondVax Announces Upcoming Expiration of Public Warrants
Mar 24, 2020
New Directors Elected to BiondVax's Board of Directors
Mar 19, 2020
BiondVax's CEO Comments on Impact of COVID-19 Pandemic on the Company's Ongoing Phase 3 Clinical Trial
Feb 05, 2020
Preliminary Data from NIH/NIAID-sponsored Phase 2 Clinical Trial of BiondVax's M-001 Universal Influenza Vaccine Candidate Validates Results of Previous Clinical Trials
Jan 16, 2020
BiondVax Announces Warrant Agreement Amendment to Permit Holders of Warrants to Exercise Both on a Cash and Cashless Basis
Nov 26, 2019
BiondVax Announces Third Quarter 2019 Financial Results and Business Update